MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

Clinical trial NCT00506077 · COMPLETED

Trial details

NCT number: NCT00506077
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Paranoid Schizophrenia

Start date: 2007-12-01
Primary completion: 2008-10-01
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.